This excerpt taken from the UNH 8-K filed Dec 19, 2006.
Latin American Acquisition, Creation of i3 in India Are Latest Key Components
BASKING RIDGE, NJ, December 7, 2006 Pharmaceutical services company i3 today announced the next phase of its global expansion, which includes organic and acquired growth in India, Latin America, and Eastern and Western Europe. Coupled with important acquisitions earlier this year in Canada and Asia/Pacific, these additions to the i3 family will help i3s pharmaceutical clients bring high-quality, well-tested drugs to market faster and more affordably by augmenting i3s ability to provide customers access to a large pool of patients and investigators and the most efficient services from across the globe. They will further enhance i3s position as a leading specialized pharmaceutical services organization in the world.
Our strategy of increased geographic reach continues to honor i3s responsibility to our customers, said Glenn Bilawsky, CEO of i3. Pharmaceutical companies want to expedite development and gain cost efficiencies through well-run trials that are completed on time and on budget. Our expansion will help us accomplish those goals while still maintaining i3s commitment to specialization and quality, which has become an industry hallmark.